COBALT advised Pfizer’s Upjohn spin-off on merger with Mylan NV

COBALT provided Latvian law advice to Pfizer’s off-patented branded and generic medicines business Upjohn on merger transaction with Mylan NV and formation of a new joint venture Viatris Inc.

The transaction was announced in 2019 and it was closed on 16 November 2020.

Newly established healthcare company Viatris Inc. employs approximately 45 000 employees and its global portfolio comprises more than 1 400 medicines.

Within transaction, the COBALT team included Partner Indriķis Liepa and Associates Jānis Sarāns and Ivo Maskalāns.